Lonza boosts exosome capability with Codiak BioSciences facility acquisition
The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies
In line with its strategy to advance the rapidly emerging specialty of exosome technology, Lonza has announced its acquisition of an exosome manufacturing facility located in Lexington, Massachusetts (US) from Codiak BioSciences.
As part of the deal Codiak — a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics — will receive approximately $65 million of “in kind” manufacturing services for its clinical-stage programmes. It will also retain its pipeline of therapeutic candidates as well as its exosome engineering and drug-loading technologies.
Lonza on the other hand will gain worldwide access and sub-licensable rights to Codiak's high-throughput perfusion-based process for exosome manufacturing.
Together, the companies plan to establish a Centre of Excellence that will leverage the strengths of both to advance developments in exosome production, purification and analytics. The centre will also provide Lonza customers with exosome assay and process development, analytics and manufacturing services.
According to Alberto Santagostino, SVP, Head of Cell and Gene Technologies at Lonza, exosomes could become the “next frontier in biotherapeutics”.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.